Abstract
Background Understanding the particle size distribution in the air and patterns of environmental contamination of SARS-CoV-2 is essential for infection prevention policies.
Objective To detect the surface and air contamination by SARS-CoV-2 and study the associated patient-level factors.
Design Cross-sectional study.
Setting Airborne infection isolation rooms (AIIRs) at the National Centre for Infectious Diseases, Singapore.
Patients COVID-19 inpatients with a positive PCR test for SARS-CoV-2 within 72 hours before the environmental sampling.
Measurements Extent of environmental surface contamination in AIIRs of 30 COVID-19 patients by PCR on environmental swabs. The particle size distribution of SARS-CoV-2 in the air was measured using NIOSH air samplers.
Results 245 surface samples were collected from 30 rooms of COVID-19 patients, and air sampling was conducted in 3 rooms. 56.7% of the rooms had at least one environmental surface contaminated, with 18.5% of the toilet seats and toilet flush button being contaminated. High touch surface contamination was shown in ten (66.7%) out of 15 patients in the first week of illness, and three (20%) beyond the first week of illness (p = 0.010). Air sampling of two COVID-19 patients (both day 5 of symptoms) detected SARS-CoV-2 PCR-positive particles of sizes >4 µm and 1-4 µm. In a single subject at day 9 of symptoms, no SARS-CoV-2 PCR-positive particles were detected.
Limitations Viral culture results were not available to assess the viability of the virus contaminating the air and surface.
Conclusion Environmental contamination was detected in rooms with COVID-19 patients in early stages of illness, but was significantly less after day 7 of disease. Under AIIR conditions, SARS-CoV-2 respiratory particles can be detected at sizes 1-4 µm and >4 µm in diameter in the air which warrants further studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is funded by NMRC Seed Funding Program (TR19NMR119SD), NMRC COVID-19 Research Fund (COVID19RF-001) and internal funds from DSO National Laboratories. Ng OT is supported by NMRC Clinician Scientist Award (MOH-000276). K Marimuthu is supported by NMRC CS-IRG (CIRG18Nov-0034). Chia PY is supported by NMRC Research Training Fellowship (NMRC/Fellowship/0056/2018).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript has been stored on a secure server with access by the authors.
